Brilinta Tablet
Product Images NDC 55154-9618

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Brilinta (NDC 55154-9618). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

8666a5c2 0bb9 4cd4 8d82 E91a108e8397 00

BRILINTA 90 mg tablet label showing product name, generic name (ticagrelor tablets), strength, and quantity containing approximately 1440 tablets. The label includes warnings to keep out of reach of children and usage as prescription drug for adult dosage. It also displays the barcode, manufacturer Cardinal Health 107, LLC, and distributor information with address in Dublin, OH.*

FDA Label Image

Figure 1

A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg and Clopidogrel in patients over 360 days from first study drug dose. The y-axis shows cumulative percentage, and the x-axis shows days. The graph indicates slightly higher event rates for Ticagrelor versus Clopidogrel throughout the study duration.*

FDA Label Image

Figure 2

A bar chart showing the percentage of patients who had an event following CABG over days 1 to 8 and beyond. The chart compares two groups labeled T and C, with values provided for each day and group. The y-axis represents the percentage of patients, and the x-axis represents the days post-CABG. Below the chart, patient counts for each group and day are displayed.*

FDA Label Image

Chemical Structure

Chemical structure of Ticagrelor, the active ingredient in BRILINTA 90 mg oral tablets. The diagram shows the molecular configuration including rings, functional groups, and fluorine atoms.*

FDA Label Image

Figure 08

A scatter plot titled 'Mean effect and 90% CI' showing pharmacokinetic interactions of Ticagrelor with various interacting drugs. The x-axis represents the change relative to reference for parameters Cmax and AUC, indicated by squares and triangles respectively, with drugs listed on the left and recommendations on the right. Data points demonstrate the impact of strong/moderate CYP3A4 inhibitors, potent CYP3A4 inducers, aspirin, and other agents on Ticagrelor exposure, along with dose adjustment recommendations.*

FDA Label Image

Figure 10

A Kaplan-Meier curve comparing cumulative event percentages over 360 days from randomization for BRILINTA (ticagrelor) 90 mg versus clopidogrel. The graph shows cumulative percent on the y-axis and days on the x-axis, with ticagrelor represented by a solid line and clopidogrel by a dashed line. The figure includes patient numbers at risk, event counts, hazard ratio, confidence intervals, and p-value comparing outcomes between treatments.*

FDA Label Image

Figure 11

A forest plot chart showing the overall treatment effect and subgroup analyses comparing Ticagrelor to Clopidogrel. The chart displays hazard ratios with 95% confidence intervals across various patient characteristics such as geographic region, aspirin daily dose, treatment approach, diabetes history, age, sex, and race, illustrating relative effectiveness outcomes.*

FDA Label Image

Figure 12

A forest plot chart comparing hazard ratios (HR) and 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across different aspirin dose groups and regions (US and Non-US). The chart includes sample sizes (N) and event counts (E) for each group, with a vertical reference line at HR=1 separating Ticagrelor and Clopidogrel effectiveness.*

FDA Label Image

Figure 13

A cumulative percentage line graph showing event rates over time in days following randomization for three groups: Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo. The graph includes the number of patients at risk at various time points up to approximately 1320 days, and presents hazard ratios and p-values comparing the treatment groups to placebo.*

FDA Label Image

Figure 14

A forest plot chart illustrating the overall treatment effect and subgroup analyses of Ticagrelor compared to placebo. The chart displays hazard ratios with 95% confidence intervals for various patient characteristics such as age group, sex, race, weight, BMI, geographic region, medical history, qualifying myocardial infarction type, diabetes status, coronary artery disease presence, creatinine clearance, PCI history, stent type, smoking status, and time since previous ADP receptor blocker treatment.*

FDA Label Image

Figure 15

A line graph depicting cumulative percentages over months from randomization comparing Ticagrelor and placebo groups. The solid line represents Ticagrelor, while the dashed line represents placebo. The graph includes a legend with event counts and numbers at risk shown below the x-axis across different months.*

FDA Label Image

Figure 16

A forest plot chart depicting hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor and placebo across various patient characteristics. The chart includes subgroups such as age, sex, race, body mass index, geographic region, aspirin dose, HbA1c, eGFR, insulin use, history of angina, coronary artery disease, PCI, CABG, smoking status, and duration of diabetes. The x-axis ranges from 0.5 to 2, indicating the direction of effect for Ticagrelor versus placebo.*

FDA Label Image

Figure 17

A Kaplan-Meier curve comparing cumulative percentage events over 34 days from randomization for Ticagrelor 90 mg twice daily versus placebo. The solid line represents Ticagrelor with fewer cumulative events (5.4%) compared to placebo shown with a dashed line (6.5%). The chart includes risk table counts for each group at various time points up to day 34.*

FDA Label Image

Figure 18

A forest plot chart illustrating the hazard ratios (HR) with 95% confidence intervals (CI) for various patient characteristics comparing Ticagrelor versus placebo effectiveness. Characteristics include age groups, sex, race, weight, BMI, geographic region, diagnosis, timing of events, comorbidities, and smoking status, with HR values visually represented by squares and horizontal lines indicating confidence intervals across a scale from 0.5 to 2.0.*

FDA Label Image

Figure 3

A line graph showing cumulative percentage (%) over months from randomization for two groups: Ticagrelor and Placebo. The y-axis represents cumulative percentage, and the x-axis represents months with data points up to 54 months. The graph includes a legend comparing events and total subjects (Ticagrelor: 206/9562, Placebo: 100/9531). Below the x-axis, numbers at risk for each group are listed across months.*

FDA Label Image

Figure 4

A cumulative percentage line graph comparing Ticagrelor 90 mg twice daily versus placebo over 34 days from randomization. The solid line represents Ticagrelor with higher cumulative events, and the dashed line represents placebo with fewer events. The x-axis shows days, and the y-axis shows cumulative percentage. A risk table below the x-axis lists participant numbers at multiple time points for both groups.*

FDA Label Image

Figure 5

A line graph comparing IPA (%) induced by 20uM ADP over time (hours) for three groups: Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. Ticagrelor shows a rapid increase to about 90% IPA by 2 hours, maintaining this level through 8 hours. Clopidogrel gradually rises to about 50% IPA by 8 hours. Placebo remains below 10% IPA across the same period.*

FDA Label Image

Figure 6

A line graph comparing IPA (%) induced by 20 μM ADP over time for three treatments: Ticagrelor, Clopidogrel, and Placebo. Time is shown in days on the x-axis and IPA (%) on the y-axis. Ticagrelor and Clopidogrel show a decline in IPA over 10 days, with Placebo consistently low. An inset graph displays IPA over hours for the same treatments.*

FDA Label Image

Figure 7

A chart titled 'Mean effect and 90% CI' comparing Ticagrelor and AR-C124910XX across intrinsic factors such as age, gender, ethnicity, renal impairment, and hepatic impairment. The x-axis measures change relative to reference from 0 to 2.5. Recommendations indicate no dose adjustment for all factors. Legend shows squares for Cmax and triangles for AUC pharmacokinetic parameters.*

FDA Label Image

Image 09

A forest plot chart showing drug interaction effects of Ticagrelor at various doses on the pharmacokinetics (Cmax and AUC) of eight interacting drugs. The chart measures change relative to each interacting drug alone, with data points indicating no dose adjustment or specific dose recommendations, such as a maximum simvastatin dose of 40 mg when used with Ticagrelor.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.